Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


A new vaccine therapy for brain cancer


MEDIA RELEASE

29 November 2012

A new vaccine therapy for brain cancer

What do you do when you are faced with terminally ill patients that want to trial a promising immunotherapy but are too sick to provide the immune cells necessary for it to work? If you are Wellington-based Neurosurgeon Mr Martin Hunn, you head back to the laboratory and find another way.

Glioblastoma multiforme (GBM) is a highly aggressive brain tumour, with an extremely poor prognosis.

The standard treatments for GBM are surgery, radiotherapy and chemotherapy, but the tumour rapidly becomes resistant to these therapies, making it ultimately fatal in almost all cases. There is an urgent need to develop novel therapies for this disease.

“We hypothesised that by acting through entirely different mechanisms, therapies that activate the immune system might succeed in attacking GBM tumours where standard treatments have failed,” says Mr Hunn.

Immunotherapy has been explored as a potential treatment option for brain cancers for some time. Here in New Zealand, Mr Hunn, along with colleagues at Wellington Hospital and the Malaghan Institute, recently completed a Phase I GBM vaccine trial at Wellington Hospital, the outcomes of which will be available next year.

The vaccines used in these trials are typically created from the patient’s tumour tissue – the target, and dendritic cells - the immune cells that direct the anti-tumour immune response.

“The problem however is that some GBM patients are so unwell it can be difficult to isolate enough dendritic cells from their blood to prepare a vaccine,” says Mr Hunn.

In parallel to his clinical work, Mr Hunn therefore undertook some laboratory-based research in collaboration with Associate Professor Ian Hermans and colleagues from the Malaghan Institute, to see if they could simplify their approach by removing the need for dendritic cells to be present in the vaccine.

Their research, published recently in the peer-reviewed international journal Clinical Cancer Research, shows that a vaccine consisting of only tumour cells and an immune-boosting adjuvant is an effective treatment for brain tumours (gliomas) in a mouse model.

“Our research has shown that we can evoke a tumour-specific, long-lasting immune response that is strong enough to kill glioma tumours by targeting the activation of dendritic cells already present inside the mouse,” says Mr Hunn. “In some instances we saw the complete disappearance of tumour lesions as detected by magnetic resonance imaging.”

One of the reasons Mr Hunn thinks this new immunotherapy approach has such great promise is because of the adjuvant included in the vaccine to boost the anti-tumour immune response – a compound derived from marine sponges called alpha-galactosylceramide (alpha-GalCer).

While this new vaccine therapy has been developed in mice, early indications are that GBM cancer patients have the immune system ‘machinery’ required for the therapy to work equally well in humans.

”We believe our research has identified a simple vaccine that could be an effective treatment for a group of patients who currently face an extremely poor prognosis,” says Mr Hunn.

This research was supported by the Cancer Society of New Zealand, the Neurological Foundation of New Zealand, the Wellington Medical Research Foundation and Just Paterson Real Estate. Mr Hunn was supported by a New Zealand Health Research Council Clinical Fellowship, the Royal Australasian College of Surgeons and the Surgical Research Trust.

Research Publication Details
Hunn MK, Farrand KJ, Broadley KW, Weinkove R, Ferguson P, Miller RJ, Field CS, Petersen T, McConnell MJ, Hermans IF Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma. Clin Cancer Res, 2012 Nov 12 [Epub ahead of print]

About the Malaghan Institute of Medical Research
The Malaghan Institute of Medical Research is New Zealand’s leading vaccine and immunology research institute and is based at Victoria University of Wellington’s Kelburn campus. The Institute operates independently and is a charitable trust. Researchers at the Malaghan Institute are focused on developing innovative ways to harness the strength and potency of the immune system, the body’s own natural defence against disease, to treat cancer, asthma and allergy, arthritis, multiple sclerosis and infectious disease.


Mr Martin Hunn

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

BusinessDesk: APN's NZME Sees Future In Paywalls, Growth In Digital Sales

APN News & Media has touted a single newsroom concept for its NZME unit in New Zealand, similar to what Germany's Die Welt uses, saying an 'integrated sales proposition' is helping it win market share, including ... More>>

Labour Party: Global Milk Prices Now Lowest In 6 Years

The latest fall in the global dairy price has brought it to the lowest level in six years and shows there must be meaningful action in tomorrow’s Budget to diversify the economy, says Labour’s Finance spokesperson Grant Robertson. “Dairy prices ... More>>

BusinessDesk: NZ Inflation Expectations Creep Higher In June Survey

May 19 (BusinessDesk) - New Zealand businesses lifted their expectations for inflation over the next two years, sapping any immediate pressure on the Reserve Bank to cut interest rates, and prompting the kiwi dollar to jump higher. More>>

BusinessDesk: Lower Fuel Costs Drive Down NZ Producer Input, Output Prices

May 19 - Producer input and output prices fell in the first quarter, mainly reflecting lower fuel costs and weakness in prices of meat and dairy products. More>>

Media: Fairfax Media NZ Announces Senior Editorial Team

Fairfax Media New Zealand has today confirmed its new editorial leadership team, as part of a transformation of its newsrooms aimed at enhancing local and national journalism across digital and print. More>>

Science: Flavonoids Reduce Cold And Cough Risk

Flavonoids reduce cold and cough risk Research from the University of Auckland shows eating flavonoids – found in green tea, apples, blueberries, cocoa, red wine and onions – can significantly reduce the risk of catching colds and coughs. The research, ... More>>


BusinessDesk: RBNZ House Alert Speech The Catalyst For Government Action

Prime Minister John Key all but conceded that pressure from the Reserve Bank of New Zealand for concerted action on rampant Auckland house prices was one of the main catalysts for the government's weekend announcements about tightly ... More>>

BusinessDesk: How To Fall Foul Of The New Housing Tax Rules: Tips From IRD

Just because you rented out your investment property doesn't absolve you from paying tax, says the Inland Revenue Department in a summary of commonly made mistakes by non-professional property investors when it comes to their tax liability.More>>

Legal: Superdiversity Law, Policy And Business Stocktake Announced

Mai Chen, Managing Partner at Chen Palmer New Zealand Public and Employment Law Specialists and Adjunct Professor of Law at the University of Auckland, today announced the establishment ... More>>

Housing: More House Price Gains Expected

House price expectations remain high, with a net 56% of respondents expecting house prices will increase. Fears of higher interest rates are fading, consistent with the RBNZ’s signals this year. Affordability and a lack of houses for ... More>>

TDDA: State-Of-The-Art Drug Testing Laboratory To Open In Auckland

World leading drug testing agencies, The Drug Detection Agency (TDDA) and Omega Laboratories, open New Zealand laboratory More>>

Network: Bigpipe Launches Ultra-Fast Broadband Into Wellington

Bigpipe Launches Ultra-Fast Broadband into Wellington Naked broadband provider Bigpipe has extended its national reach, announcing today, the launch of its unlimited UFB offering into Wellington. The Spark Venture business is giving Wellingtonians the ... More>>

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news